Innate Pharma S.A. (FR:IPH) has released an update.
Innate Pharma S.A. has announced the selection of four abstracts featuring their innovative cancer treatments, SAR443579 and IPH6501, for presentation at the EHA 2024 Congress. These drugs, part of Innate’s ANKET® platform, show promise in treating blood cancers and Non-Hodgkin’s Lymphomas with high unmet needs. The company, in collaboration with Sanofi, is advancing these therapies through clinical trials, aiming to provide new options for patients with difficult-to-treat cancers.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
